The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. However, most patients do not achieve stable disease remission with currently available immunotherapies.
is made up of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. Candel is built on excellent science, and our experienced team is helping translate its full promise to patients.
President & Chief
Executive Officer
Founder & Chief
Scientific Officer
Charu Aggarwal, M.D., MPH
Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
Steven M. Albelda, M.D.
Professor of Medicine and Vice Chief, Pulmonary, Allergy and Critical Care Division, Thoracic Research Laboratory, University of Pennsylvania
Mark Bloomston, M.D.
Medical Director, South Florida Surgical Oncology
E. Antonio Chiocca, M.D., Ph.D.
Chair, Department of Neurosurgery Brigham and Women’s Hospital and Professor, Harvard Medical School
Scott Eggener, M.D.
Professor of Surgery and Radiology, Vice Chair of Urology, Director High Risk and Advanced Prostate Cancer Clinic, University of Chicago
Adam Kibel, M.D.
Chief, Division of Urology Brigham and Women’s Hospital and Professor, Harvard Medical School
Tri Le, M.D.
Assistant Professor, Medicine, Hematology and Oncology, University of Virginia
Daniel H. Sterman, M.D.
Professor and Director, Pulmonary, Critical Care and Sleep Medicine, NYU Langone Health
Patrick Y. Wen, M.D.
Director, Center for Neuro-Oncology Dana-Farber Cancer Institute and Professor, Neurology, Harvard Medical School
Sunil Singhal, M.D.
Assistant Professor of Surgery, University of Pennsylvania School of Medicine
